Curachem큐라켐

Curachem is a small KONEX-listed drug development services firm with no financial statements in the data provided.

Curachem is a Korean contract research and manufacturing firm that works for drug developers, including making radioactive isotopes used in drug testing. The shares closed at ₩7,210 on 2026-10-28, with a market value of about ₩13.2B, and sit within a 52-week range of ₩6,790 to ₩7,640. The data contains no annual or trailing financial results, so the current size of the business cannot be measured from it.

What stands out

• Recent price action is flat: the share price shows 0% over one month and three months, and +1.5% over one year.
• No annual or trailing-twelve-month financials are included, and no valuation multiples (P/E, P/B, P/S, EV/EBITDA) can be calculated.
• Foreign and institutional net flows over the last 20 days are shown as zero, and foreign ownership is 0% now and 60 days ago.
• Recent filings are mostly routine: an annual report for Dec 2025, the March 2026 AGM results, IR events, and a June 2026 filing on conversion rights for convertible shares.
• No news headlines were found in the data for this company.

What to watch

• Whether the convertible share conversion exercised in June 2026 changes the number of listed shares, which stood at 1,834,286 in the data.
• The next annual or interim financial filings, since none of the company's revenue or profit figures are in the data yet.
• Any new filings or news on the company's contract research and manufacturing business, which the data does not describe in detail.